CSF2 and autoimmune pulmonary alveolar proteinosis: In 2020, a double-blind, placebo-controlled, three-group trial assigned patients with autoimmune PAP to receive the recombinant GM-CSF molgramostim (300 μg once daily by inhalation), either continuously or intermittently (every other week), or matching placebo.